TY  - GEN
N2  - Osteosarcoma (OS) is the most common form of primary malignant bone cancer, predominantly
affecting children and young adults. Despite extensive research at the genomic and transcriptomic
levels, advances in the treatment of OS have been limited, and patients with treatment-resistant OS
continue to face particularly poor overall survival rates. This thesis presents a comprehensive multiomics analysis aimed at identifying the targetable proteomic landscape of treatment-resistant OS.
Through unbiased mass spectrometry-based proteomic profiling, I identified three distinct subtypes
of treatment-resistant OS, each associated with varying survival outcomes. Notably, in one subtype
associated with poor overall survival, upregulation of MYC signalling and MYC activity emerged as
prominent features. Subsequent in vitro experiments targeting this subtype through inhibition of MYC
kinases CDK2 and CDK5 demonstrated potential therapeutic benefits. Overall, this work provides a
detailed multi-omics characterization of treatment-resistant OS, offering insights into novel
therapeutic options that may improve patient outcomes.
ID  - heidok36797
UR  - https://archiv.ub.uni-heidelberg.de/volltextserver/36797/
AV  - restricted
CY  - Heidelberg
A1  - Frenz, Joris Maximilian
Y1  - 2025///
TI  - Proteogenomics of Treatment Resistant Osteosarcoma
ER  -